These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24589338)

  • 1. CD133-targeted niche-dependent therapy in cancer: a multipronged approach.
    Mak AB; Schnegg C; Lai CY; Ghosh S; Yang MH; Moffat J; Hsu MY
    Am J Pathol; 2014 May; 184(5):1256-62. PubMed ID: 24589338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
    Song WC; Fei XF; Dong J
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
    Lai CY; Schwartz BE; Hsu MY
    Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
    Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
    Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research progression of CD133 as a marker of cancer stem cells.
    Zhang H; Li SY
    Chin J Cancer; 2010 Mar; 29(3):243-7. PubMed ID: 20193104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
    Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
    Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
    Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
    J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha.
    Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM
    Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1 collagen as a potential niche component for CD133-positive glioblastoma cells.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Houkin K
    Neuropathology; 2014 Aug; 34(4):378-85. PubMed ID: 24673436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
    Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
    J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
    Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
    Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
    Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
    Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
    Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
    Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How powerful is CD133 as a cancer stem cell marker in brain tumors?
    Cheng JX; Liu BL; Zhang X
    Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CD133 antigen in cancer.
    Ferrandina G; Petrillo M; Bonanno G; Scambia G
    Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.
    Zhang Q; Shi S; Yen Y; Brown J; Ta JQ; Le AD
    Cancer Lett; 2010 Mar; 289(2):151-60. PubMed ID: 19748175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.